Literature DB >> 9106461

Dopamine D1 and D2 receptor binding sites in brain samples from depressed suicides and controls.

C Bowden1, A E Theodorou, S C Cheetham, S Lowther, C L Katona, M R Crompton, R W Horton.   

Abstract

Dopamine D1 and D2 receptors were measured (by saturation binding of [3H]SCH23390 and [3H]raclopride) in caudate, putamen and nucleus accumbens, obtained at post-mortem from suicide victims with a firm retrospective diagnosis of depression, and matched controls. There were no differences in the number or affinity of D1 or D2 receptors between suicides who had been free of antidepressants for at least three months prior to death, and controls. Increased numbers and decreased affinity of D2 receptors were however found in each brain region of antidepressant-treated suicides. We argue that these increases are related to concurrent treatment with neuroleptics rather than a direct effect of antidepressants. Increased numbers of D1 receptors in antidepressant-treated suicides were seen only in nucleus accumbens. This increase could not be clearly attributed to neuroleptics and may be related to antidepressant treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9106461     DOI: 10.1016/s0006-8993(96)01460-6

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  15 in total

1.  Genetic NMDA receptor deficiency disrupts acute and chronic effects of cocaine but not amphetamine.

Authors:  Amy J Ramsey; Aki Laakso; Michel Cyr; Tatyana D Sotnikova; Ali Salahpour; Ivan O Medvedev; Linda A Dykstra; Raul R Gainetdinov; Marc G Caron
Journal:  Neuropsychopharmacology       Date:  2008-01-09       Impact factor: 7.853

Review 2.  Positron emission tomography molecular imaging in late-life depression.

Authors:  Kentaro Hirao; Gwenn S Smith
Journal:  J Geriatr Psychiatry Neurol       Date:  2014-01-05       Impact factor: 2.680

Review 3.  Stress, genes and the biology of suicidal behavior.

Authors:  Dianne Currier; J John Mann
Journal:  Psychiatr Clin North Am       Date:  2008-06

Review 4.  Toward a biosignature for suicide.

Authors:  Maria A Oquendo; Gregory M Sullivan; Katherin Sudol; Enrique Baca-Garcia; Barbara H Stanley; M Elizabeth Sublette; J John Mann
Journal:  Am J Psychiatry       Date:  2014-10-31       Impact factor: 18.112

5.  The subjective and cognitive effects of acute phenylalanine and tyrosine depletion in patients recovered from depression.

Authors:  Jonathan P Roiser; Andrew McLean; Alan D Ogilvie; Andrew D Blackwell; Diane J Bamber; Ian Goodyer; Peter B Jones; Barbara J Sahakian
Journal:  Neuropsychopharmacology       Date:  2005-04       Impact factor: 7.853

Review 6.  Aripiprazole as adjunctive therapy for patients with major depressive disorder: overview and implications of clinical trial data.

Authors:  Chi-Un Pae; Andy Forbes; Ashwin A Patkar
Journal:  CNS Drugs       Date:  2011-02       Impact factor: 5.749

7.  Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression.

Authors:  Adolfo Sequeira; Firoza Mamdani; Carl Ernst; Marquis P Vawter; William E Bunney; Veronique Lebel; Sonia Rehal; Tim Klempan; Alain Gratton; Chawki Benkelfat; Guy A Rouleau; Naguib Mechawar; Gustavo Turecki
Journal:  PLoS One       Date:  2009-08-11       Impact factor: 3.240

Review 8.  The neurobiology of retinoic acid in affective disorders.

Authors:  J Douglas Bremner; Peter McCaffery
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2007-07-10       Impact factor: 5.067

Review 9.  Aripiprazole in the treatment of depressive and anxiety disorders: a review of current evidence.

Authors:  Chi-Un Pae; Alessandro Serretti; Ashwin A Patkar; Praksh S Masand
Journal:  CNS Drugs       Date:  2008       Impact factor: 5.749

10.  Dopamine type-1 receptor binding in major depressive disorder assessed using positron emission tomography and [11C]NNC-112.

Authors:  Dara M Cannon; Jacqueline M Klaver; Summer A Peck; Denise Rallis-Voak; Kristine Erickson; Wayne C Drevets
Journal:  Neuropsychopharmacology       Date:  2008-10-22       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.